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 control phenotype transitions [version 1; referees: 1 approved, 2
approved with reservations]
Lina D. Thomas ,    Dariia Vyshenska , Natalia Shulzhenko , Anatoly Yambartsev ,
Andrey Morgun2
Instituto de Matemática e Estatística, Universidade de São Paulo, São Paulo, Brazil
College of Pharmacy, Oregon State University, Corvallis, USA
College of Veterinary Medicine, Oregon State University, Corvallis, USA
Abstract
Background: Co-expression networks are a tool widely used for analysis of “Big
Data” in biology that can range from transcriptomes to proteomes,
metabolomes and more recently even microbiomes. Several methods were
proposed to answer biological questions interrogating these networks.
Differential co-expression analysis is a recent approach that measures how
gene interactions change when a biological system transitions from one state to
another. Although the importance of differentially co-expressed genes to
identify dysregulated pathways has been noted, their role in gene regulation is
not well studied. Herein we investigated differentially co-expressed genes in a
relatively simple mono-causal process (B lymphocyte deficiency) and in a
complex multi-causal system (cervical cancer).
Methods: Co-expression networks of B cell deficiency (Control and BcKO)
were reconstructed using Pearson correlation coefficient for two mus musculus
datasets: B10.A strain (12 normal, 12 BcKO) and BALB/c strain (10 normal, 10
BcKO). Co-expression networks of cervical cancer (normal and cancer) were
reconstructed using local partial correlation method for five datasets (total of 64
normal, 148 cancer). Differentially correlated pairs were identified along with
the location of their genes in BcKO and in cancer networks. Minimum Shortest
Path and Bi-partite Betweenness Centrality where statistically evaluated for
differentially co-expressed genes in corresponding networks.   
Results: We show that in B cell deficiency the differentially co-expressed genes
are highly enriched with immunoglobulin genes (causal genes). In cancer we
found that differentially co-expressed genes act as “bottlenecks” rather than
causal drivers with most flows that come from the key driver genes to the
peripheral genes passing through differentially co-expressed genes. Using in
 knockdown experiments for two out of 14 differentially co-expressedvitro
genes found in cervical cancer (FGFR2 and CACYBP), we showed that they
play regulatory roles in cancer cell growth.
Conclusion: Identifying differentially co-expressed genes in co-expression
networks is an important tool in detecting regulatory genes involved in
alterations of phenotype.
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Introduction
Recent technological advances have moved the focus of biologists 
from how to measure biological parameters to how to analyze and 
interpret tens of thousands of measurements, frequently called 
omics data. The first solutions for such a problem were limited 
to hierarchical clustering1–3 and simple comparisons between 
classes of data through the identification of differentially expressed 
genes (DEGs)4,5. Nowadays, reconstruction and interrogation of 
biological networks have become a widely used approach to get 
insights from different types of omics data6,7.
After establishing co-expression networks for different states of 
one biological system, differential co-expression analysis investi-
gates their structural changes when a system goes through a state 
transition. This analysis, first proposed more than a decade ago8,9, 
identifies the pairs of genes that have their interaction changed 
during such transition. Several later publications have suggested 
different algorithms and statistics to determine differential gene 
co-expression10–27. Fewer studies, however, attempted to evaluate 
the biological significance of these changes18,21. Also, to the best of 
our knowledge, there have been no studies that would investigate 
how this approach performs depending on the type and complexity 
of the biological system analyzed.
Commonly, a state transition of a biological system is related to 
perturbation of a set of genes, which propagates through network 
interactions and affects other genes. Thus, there is a possibility that 
differentially co-expressed (DC) genes (directly or indirectly) con-
tribute to the propagation of perturbations. In order to investigate 
the role of DC genes in a state transition of a biological system, we 
considered two biological processes28,29 previously analyzed by our 
group. The first one (B cell deficiency in mice) is a homogenous, 
one-causal-factor process, while the second one (cervical cancer) 
represents a heterogeneous multi-causal system.
In this work, a co-expression network is an undirected graph, where 
the set of nodes consists of a set of DEGs, and a pair of nodes 
is connected if there is a significant correlation between them. 
Differential co-expression analysis is done by identifying the pairs 
of genes that suffer significant changes in correlation between two 
states. Throughout this paper such pairs are called differentially 
correlated pairs (DCPs) and the genes forming these pairs are con-
sidered DC genes.
Results
B cell deficiency
We started by analyzing the B cell knockout (BcKO) data28, which 
represents a relatively simple experimental model with only one 
causal factor (B lymphocytes) and homogenous subject groups 
since this experiment was performed in highly inbred strains of 
mice.
In order to select the nodes to reconstruct the co-expression 
networks (BcKO and Control) we compared gene expression in 
jejunum between BcKO and control mice and found 509 DEGs 
(Dataset 1). Next, the edges for each network were determined 
using significantly correlated pairs of DEGs (Figure 1). To 
identify DCPs we used the method introduced in21 which compares 
correlations in the BcKO group and in the Control group. Eighty 
DCPs were found (Dataset 2), of which 56 represent correla-
tion gains (edges which were not present in Control network but 
showed up in BcKO) and 24 represent losses.
Figure 1. Co-expression networks for BcKO data. The nodes are composed by DEGs and the edges represent significant correlations 
between nodes. The causal genes (immunoglobulin genes) and the DCP edges are concentrated in the high connectivity region with several 
causal genes forming DCPs.
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Dataset 1. Differentially expressed genes from BcKO study
http://dx.doi.org/10.5256/f1000research.9708.d142100
Contains p-values, ratios of expression means, combined Fisher’s 
p-value, fdr, direction of regulation, whether it is Ig gene and whether 
it is DC gene.
Dataset 2. Differentially correlated pairs from BcKO study
http://dx.doi.org/10.5256/f1000research.9708.d142099
Contains information such as “change direction” (whether each pair 
gained or lost correlation/edge), “sign of local partial correlation” 
in BcKO data and control data, “regulation” (whether each gene of 
each pair is up- or down-regulated in BcKO), “number of Ig genes” 
in each pair.
Now we investigate whether network structural changes, herein 
represented by DCPs, are related to actual causes of global change 
in gene expression. In the previous study28, it was shown that 
intestinal gene expression alterations in BcKO mice are mostly 
dependent on the ability of B lymphocytes to produce antibodies. 
Therefore, we analyzed the presence of immunoglobulin coding 
genes (Ig genes, see Dataset 3) among differentially expressed 
genes (26 Ig genes among 509 DEGs) in DCPs. We observed 
that 72% (39 out of 54) of correlation gain DCPs are formed by 
at least one Ig gene, (Figure 2A). Moreover, we found strong 
enrichment for Ig genes among DC genes in correlation gain (24% 
(15 out of 63) of DC genes are Ig genes vs 2.7% (11 out of 415) 
of other DEGs are Ig genes), while no enrichment was observed 
for correlation lost as a result of B cell deficiency (Figure 2B). 
Thus, these results support the idea that differentially expressed 
genes that acquire correlations during transition from one 
biological state to another have a high chance to play causal roles 
in such transition.
Dataset 3. Causal genes from BcKO study
http://dx.doi.org/10.5256/f1000research.9708.d142097
Contains the Ig genes considered causal along with annotation and 
whether they are considered DC genes or not.
Figure 2. A) 78 Differentially Correlated Pairs (DCPs) were found, of which 54 represent correlation gains (edges which were not present in 
Control network but showed up in BcKO) and 24 represent correlation losses. The table stratifies the set of pairs representing correlation gains 
and losses according to the amount of Ig genes (0, 1 or 2) present in a pair. Note that 39 out of 54 of correlation gain DCPs are formed by at 
least one Ig gene while only 2 out of 22 correlation losses have at least one Ig gene. B) The 78 DCPs are formed by a total of 94 Differentially 
Co-expressed genes (DC genes). 58 DC genes participate only in correlation gain DCPs, 31 only in correlation loss DCPs and 5 of them 
participate in both correlation gain and loss DCPs. The results show enrichment for Ig genes among DC genes in correlation gain: 24% (15 
out of 63 (=58+5)) of DC genes are Ig genes vs 2.7% (11 out of 415) of other DEGs are Ig genes (p value < 0.001). Meanwhile no enrichment 
was observed for correlation loss as a result of B cell deficiency: 3% (1 out of 36 (=31+5)) of DC genes are Ig genes vs 2.7% (11 out of 415) 
of other DEGs are Ig genes.
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Cervical cancer
Analysis of gene expression data. In order to study differentially 
co-expressed genes in a more complex biological model we turned 
to cancer. It is well known that cancers of the same clinically/ 
morphological type can be very different on molecular levels. One 
of the most studied causes for such diversity is the different sets 
of chromosomal aberrations and mutations harbored by tumors 
otherwise defined as the same cancer. In previous study29, we 
have found 36 cervical cancer driver genes located in multiple 
chromosomal aberrations (Dataset 4). Thus we decided to use 
cervical cancer data from 29 for investigation of the role of DCPs 
in complex biological processes due to its heterogeneity and 
previously acquired knowledge of essential causal genes.
Dataset 4. Causal genes from cervical cancer study
http://dx.doi.org/10.5256/f1000research.9708.d142098
Contains the chromosomal aberration genes considered causal 
along with annotation and whether they are considered DC genes 
or not.
We used the DEGs between tumor and normal tissue as the 
nodes of the co-expression networks. Since the number of samples 
(five datasets, 148 tumor samples and 67 normal samples) was 
larger than in BcKO study (two datasets, 22 paired samples), we 
used the partial correlation coefficient as a measure of co-expres-
sion (Figure 3). The potential advantage of using partial correlation 
is that it aims to infer edges that are a result of direct regulatory 
relations6. Partial correlations were calculated through the Local 
Partial Correlation (LCP) method30 (Material and Methods).
In this study seven DCPs composed of 14 DC genes were found. 
Interestingly, all DCPs were differential correlations gained in 
tumors (Table 1). Only one of the 36 key drivers (CEP70) was 
identified among the 14 DC genes. Accordingly, no enrichment of 
key driver genes among DC genes was detected in this analysis.
Even though we observed that DCPs are not necessarily formed by 
key drivers, it is known from literature that most of the DC genes 
found play regulatory roles in other types of cancer31–48. Thus we 
hypothesized that DCPs are located downstream of key drivers and 
can be responsible for changes of regulatory chain events coming 
from the key drivers and spreading throughout the network. In order 
to verify this hypothesis, we investigated how close DC genes are 
to key drivers and whether their “signal flow”49 in the tumor co-
expression network is stronger than that of the other genes. In order 
to verify this hypothesis we investigated two network measures: 
Minimum Shortest Path and Bi-partite Betweenness Centrality.
First we compared the shortest paths from key driver genes to 
DC genes and to all other DEGs in the network. We found that 
DC genes are located statistically closer than the rest of genes in 
the network to key drivers (Figure 4A, Wilcoxon test < 0.014 and 
Permutation test < 0.021). Then we used Bi-partite Betweenness 
Centrality6 as a measure of the signal flow from key drivers to 
peripheral genes (genes with only one edge)6. We evaluated 
this measure for DC genes and remaining DEGs and observed 
that DC genes had much higher values than other genes in the 
network. Figure 4B illustrates a comparison of boxplots of 
bi-partite betweenness centrality between these two groups con-
cerning DCPs and the rest (non DCPs, non-key drivers, non- 
peripheral). We can observe that the bi-partite betweenness 
Figure 3. Co-expression networks for cervical cancer data. The nodes are composed by DEGs and the edges represent significant local 
partial correlation between nodes. A few causal genes (key drivers) and DCP edges are located in the high connectivity region, but scattered 
throughout the network. Only one key driver is amongst the genes in DCPs.
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Figure 4. Topological properties of Differentially Correlated Genes (DCGs). A) Barplot of the shortest path to the causal genes and 
originated in either the genes in DCPs (in orange) or the non DCP genes (in blue). The distribution in orange is concentrated in lower values. 
B) Boxplot comparing the values of Bipartite Betweenness Centrality of the genes in DCPs (in orange) and the non-DCP genes (in blue). The 
boxplot on the left is concentrated in higher values.
Table 1. DCPs – cancer (* key drivers).
Gene 
symbol 1
Gene 
symbol 2
Change 
direction
Sign of local partial 
correlation in tumor
Regulation 1 Regulation 2
ANP32E CACYBP Gained edge > 0 UP UP
CENPN DHFR Gained edge > 0 UP UP
C10orf68 FGFR2 Gained edge > 0 DN DN
AK2 HNRNPR Gained edge > 0 UP UP
CEP70* SEPHS1 Gained edge > 0 UP UP
NIPAL2 TRPM3 Gained edge > 0 DN DN
They stem 
ARHGEF12
ZSCAN18 Gained edge > 0 DN DN
centralities of DCPs are concentrated in higher values than the 
rest. Mann-Whitney test gave us a p-value of 7.868 X 10-5, which 
gives us evidence that the distribution of Bi-Partite Betweenness 
Centrality in DCP genes is higher. For more details see Figure S2. 
Thus, altogether these results suggest that DC genes might be 
“bottlenecks”, that is, required to transmit a signal from key 
drivers to other genes in the network, therefore, supplement 
the hypothesis of a regulatory role of DC genes (Figure S1).
Knockdown experiments. In addition, data from other cancers 
provide indirect support for the idea of regulatory role of DC genes 
in cervical cancer31–48. However, since a role of these DC genes in 
carcinogenesis was not as straightforward as for immunoglobulin 
genes in B cell deficiency, we decided to perform experimen-
tal tests. Among the DC genes found for cervical cancer, there 
were seven up-regulated and seven down-regulated in cancer. 
Therefore, for validation experiments we chose one down-regulated 
(FGFR2) and one up-regulated (CACYBP) gene that have not been 
previously studied in cervical cancer for regulatory properties, but 
have a potential connection with cell death or proliferation based 
on their Gene Ontology annotations. In order to test if FGFR2 and 
CACYBP play critical regulatory roles in cancer pathogenesis, 
we evaluated the effect on in vitro knockdown of these genes on 
cell proliferation in a cervical carcinoma cell line.
First, we tested two cervical cancer cell lines (Hela and ME180) 
and found that only ME180 had detectable expression levels of 
both genes. In order to perform these tests, we evaluated siRNAs 
and observed that they were able to knock down expression of 
both genes by at least 70% (Figure 5A). CACYBP is up-regulated 
in tumor tissue, as compared to normal tissue (Figure 5B). Con-
sequently, if CACYBP has regulatory potential, as predicted by 
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Figure 5. Experimental evaluation of DCGs in cervical cancer. A) Efficacy of FGFR2 and CACYBP siRNA knockdown. qRT-PCR with 
primers for GAPDH as the internal control was used to determine expression and efficacy of FGFR2 and CACYBP specific siRNA knockdown 
in endothelial cells (ME180). ME180 cells were harvested 72 h after transfection with vehicle (Lipofectamine) and either scrambled control 
or targeting siRNA. B) Gene expression of FGFR2 and CACYBP (mean +/- standard deviation) for tumor and normal samples from five 
datasets used in the analysis. Since FGFR2 was found down-regulated in tumor tissue, its potential regulatory role would be as a tumor 
suppressor. However, CACYBP is up-regulated, thus CACYBP should function as an oncogene promoting cell proliferation. C) Evaluation of 
cell proliferation inhibition using xCelligence System. Proliferation data (cell index) was obtained at 72 h after transfection with Lipofectamine 
and either scrambled control or targeting siRNA. Inhibition index was calculated (two step normalization of cell index): inhibition index > 0 
– cells transfected with targeting siRNA showed decrease in proliferation; < 0 – showed increase in proliferation; = 0 – no difference from 
control was found. One sided T test for mean (< 0 for FGFR2 and > 0 for CACYBP) was applied and returned statistically significant p-values 
for both of them (0.0258 for FGFR2 and 0.01978 for CACYBP).
our analysis, it should function as an oncogene promoting cell 
proliferation. Therefore, the knockdown of this gene should result 
in a decrease of cell growth/survival. Since FGFR2 was found 
down-regulated in cervical carcinomas (Figure 5B) its potential 
regulatory role would be as a tumor suppressor. Therefore, the 
knockdown of this gene is expected to increase cell growth. The 
subsequent analysis of cell proliferation confirmed our predic-
tions for both genes: knockdown of CACYBP led to a decrease of 
cell growth, while knockdown of FGFR2 induced higher cell 
proliferation (Figure 5C). Thus, these results provide additional 
support to our in silico prediction that DC genes may play a 
regulatory role in cell proliferation related to tumor growth.
Dataset 5. Cytoscape Edges and Nodes tables from network in 
Figure 1
http://dx.doi.org/10.5256/f1000research.9708.d14210
The datasets are sufficient to reproduce Figure 2.
Dataset 6. Cytoscape Edges and Nodes tables from network in 
Figure 3
http://dx.doi.org/10.5256/f1000research.9708.d142102
The datasets are sufficient to reproduce Figure 4.
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 Dataset 7. Raw data for Figure 5A,C
 http://dx.doi.org/10.5256/f1000research.9708.d142103
 Raw data for Figure 5A:
 qRT PCR siRNA test.
 Instrument Type: steponeplus
 Passive Reference: ROX
 Analysis Type: Singleplex
 Endogenous Control: GAPDH
 RQ Min/Max Confidence Level: 95.0
 Reference Sample: A
 Raw data for Figure 5C:
 Three xCellingence experiments.
Discussion
In the current study, the differential co-expression analysis21 was 
applied to two relatively well-investigated biological systems28,29 
in order to evaluate the potential importance of genes found using 
differential correlation analyses. Overall, the obtained results 
support the idea that DC genes play a regulatory role. While in 
B cell deficiency DCPs were found highly enriched with immu-
noglobulin genes (i.e. causal genes for alterations in the gut) 
we did not observe enrichment for key driver genes in cervical 
cancers. Rather, DCPs of cervical cancer seem to be located 
downstream of causal genes. Indeed, those DCPs have been found 
closer to key regulators than other genes in the network, actually 
representing “bottlenecks” for communication between driver 
genes previously published in 29 and the rest of the network 
(Figure 4). Furthermore, some differentially co-expressed genes in 
cervical cancer have been previously implicated in processes such 
as metastasis, oncogenic autophagy and apoptosis. For example, 
CACYBP has been shown to promote colorectal cancer metasta-
sis31, TRPM3 was observed to play a role in oncogenic autophagy 
in clear cell renal cell carcinoma32,33, and AK2 was reported to 
activate apoptotic pathway34. Several genes are investigated for 
prognostic value for cancers such as myeloma35, lymphoma36, 
breast37–41 and gastrointestinal42,43 cancers. At least two genes were 
previously proposed as targets for anti-cancer agents: DHFR44 and 
FGFR245. Moreover, CACYBP and ZSCAN18 were also reported 
as putative tumor suppressor genes in renal cell carcinoma30,46,47. 
In addition, we have tested two DC genes and confirmed their 
regulatory role (FGFR2 as a tumor suppressor and CACYBP as 
a potential oncogene in cervical cancer) by manipulating their 
expression in vitro. Altogether, published observations and our 
experimental validation for these two genes support the idea that 
DC genes revealed in the current study play a regulatory role and 
can be candidate targets for cervical cancer treatment.
Interestingly, while in the model of B cell deficiency, the DC genes 
are highly enriched with causal regulatory genes, there was only 
one key driver in cervical cancer (CEP70), despite the DC genes 
in this system still seeming to play a regulatory role overall. 
Such a difference is potentially related to the fact that the mouse 
system studied in 28 is highly homogeneous (inbred mice) with 
only one cause of alterations (i.e. absence of B lymphocytes). 
Cervical cancer, however, is a heterogeneous system with different 
chromosomal aberrations and consequently turned-on expression 
of different driver genes in different patients. Therefore, we can 
speculate that differential correlations point to regulatory genes 
that are shared by majority of samples. This hypothesis warrants 
further investigation, especially considering that DCPs could 
represent common therapeutic targets for tumors that originated 
as a result of different genomic or epi-genomic events.
In conclusion, this study provided additional evidence for the 
previously suggested idea8–27 that genes presenting alterations 
in correlation patterns between different phenotypes (i.e. states 
of biological system) play a critical regulatory role in transi-
tions from one state to another. Furthermore, although our results 
do not allow for full generalization, they indicate that gain and 
not loss of correlations connects critical genes involved in transi-
tions to new phenotypes. However, further studies are required to 
understand how changes in correlation patterns can point to genes 
with critical capacity to guide a biological system into certain state/
phenotype.
Material and methods
Preparation of microarray data
BcKO. All microarray data were analyzed using BRB Array-Tools 
developed by the Biometric Research Branch of the National 
Cancer Institute under the direction of R. Simon (http://linus.nci.
nih.gov/BRB-ArrayTools.html). Array data were filtered to limit 
analysis to probes with greater than 50% of samples showing 
spot intensities of >10 and spot sizes >10 pixels, and a median 
normalization was applied.
Cervical cancer. Same as in cervical cancer29. The data were 
analyzed using BRB Array-Tools using the original normalization 
used in three studies50–52 and median normalization over entire the 
array for the fourth study53. For all studies, we only considered 
genes found in at least 70% of arrays.
Filtering and meta-analysis of microarray data
In every analysis (DEGs, DCPs and networks), filter of direction 
(same sign of correspondent parameter – difference of mean, differ-
ence of correlation, correlation and partial correlation) was required 
in a fixed number of datasets (2 out of 2 in BcKO and 3 out of 5 
in cervical cancer). Then meta-analysis was done through Fisher 
combined probability test54. Next, the pairs with false discovery rate 
(fdr)55 lower than a threshold are chosen. At last, only the pairs that 
pass PUC56 are considered correlated and therefore represent edges 
in the network.
Analysis of microarray data
BcKO. DEGs between groups of samples were identified by 
random variance paired t-test p-value lower than 5% with adjust-
ment for multiple hypotheses by setting the fdr below 10% in 
BRB Array-Tools. Co-expression networks (BcKO and Control) 
were inferred through Pearson correlation with p-value < 20% and 
fdr adjustment below 2.5%. DCPs were calculated for pairs that 
were initially correlated (p-value < 20%) in at least one state. 
Then differences of Pearson correlation were tested following21 
with a p-value below 10% and fdr < 2%. At last only the DCPs 
that showed up in one of the networks were selected.
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Cervical cancer. DEGs were retrieved from a cervical can-
cer paper29. Correlation networks and DCPs followed the same 
procedure and in BcKO but with different p-values (correlation 
p-value < 10% with fdr < 10-8 and difference of correlation p-value 
< 10% with fdr < 0.25%). Partial correlation was computed using 
local partial correlation method30. The initial significance was 
p-value lower than 40% and then fdr < 5%.
For more details about the thresholds used, see Table S3 and 
Table S4.
Local partial correlation network
Two aspects of cervical cancer data motivated us to use local 
partial correlation for this system. First of all, we have more 
samples throughout five datasets (see Supplementary Table S1 
and Supplementary Table S2) which allows us to have more 
confidence in our results and second we already know that tumors 
in general present heterogeneous causal factors. The partial 
correlation approach gives us the alternative to only consider 
edges that represent direct regulatory relations.
In this paper we used the new approach developed in 30 called 
local partial correlation. This approach was elaborated specially 
for cases when there are more variables than samples, which hap-
pens regularly in genetics and is a serious problem in classical 
statistics. First we calculate the correlation network. Then for 
each significantly correlated pair the inverse method is applied 
exclusively to the correlation sub-matrix formed only by the 
closest neighbors of the pair along with the genes forming the pair, 
Figure 6. If the number of closest neighbors is still higher than the 
number of samples n, then we decreasingly rank the correlations 
of the neighbors to either genes in the pair and select the first n/2 
neighbors. For each sub- matrix, we only keep the partial correla-
tion value regarding the pair that formed that sub- matrix and then 
calculate its p-value also based on the sub- matrix. R script for 
calculation is available in Supplementary Material.
Partial correlations were estimated only for the significant 
(Pearson) correlations in co-expression network. Thus the same 
definition of DCPs (by Pearson correlation) can still represent 
structural changes as long as it remains present in one of the two 
networks.
Figure 3 illustrates the local partial correlation network for cervical 
cancer using only tumor data. It has 578 connected nodes and 824 
edges.
Figure 6.  Local partial correlation scheme: we calculate the LPC for pair X2, X5, (red nodes/edge). The neighborhood of this pair is the 
set of nodes X3, X6, X8, X9 (black nodes/edges). X1, X4, X7 (blue nodes) are significantly correlated with the black nodes (blue edges), but not 
with the red nodes. Thus the inverse method is applied exclusively to the correlation sub-matrix formed only by the genes X2, X5, X3, X6, X8, 
X9. In correlation matrices the gray entries are statistically non-significant empirical correlations.
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Minimum shortest path
The shortest path is a method that calculates distances between 2 
nodes in a network. It consists of the minimum number of edges 
connecting 2 nodes. In this case we want to know the minimum 
number of edges connecting one node, either DCP gene or not, 
to a group of nodes: the key drivers Figure 7. For each gene we 
calculate the shortest path to all key drivers and get the minimum 
value. Then we compare the minimum shortest path to key driv-
ers coming from DCP genes and the remaining genes. Figure 4A 
shows that the minimum shortest path to key drivers tend to be 
smaller when originated in DCP genes.
Bi-partite betweenness centrality
Betweenness Centrality measures the node’s centrality in a 
network by counting the number of shortest paths from all verti-
ces to all other vertices that pass through that node. A gene with 
high betweenness centrality has a great influence on the transfer 
of signal through the network Figure 8.
However we are interested in the signal passing from key drivers 
throughout the network. For this reason we decided to apply 
the measure previously developed by our lab6 called Bi-partite 
Betweenness Centrality. It measures the amount of shortest path 
Figure 7. In this example we show how to calculate the distance (length of shortest path) between the gene G2 and group of genes 
D1, D2, D3, D4 (nodes in red).
Figure 8. Here we explain how to calculate bi-partite betweenness centrality (bc) between groups A and B. Note that the node D has 
bigger bc because all shortest paths connecting nodes in group A to nodes in group B pass through the node D.
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going from all genes in one group of vertices to all genes in a 
different group of vertices. In our case, the groups of genes are the 
key drivers and the peripheral genes (genes connected to only one 
edge).
Experimental design
FGFR2 and CACYBP knockdown experiment
ME180 cells were transfected with FGFR2-, CACYBP-specific 
siRNA or control siRNA using Lipofectamine RNAiMAX 
Transfection Reagent. Cell growth rate during 72h after siRNA 
transfection was measured using xCelligence system as described 
below.
Evaluation of siRNA efficacy in knocking down the gene targets. 
ME180 cell line was obtained from Dr. Pulivarthi H. Rao. It was 
cultured in RPMI medium with 10% FBS and 1% Penicillin- 
Streptomycin added. The cells were seeded at density 4000 cells 
per well in 96 F-bottom plates (seeding procedure was done 
according to ATCC protocol for ME180 cell line) and with cell 
culture media 200 ul per well. 24 hours after seeding, cells were 
transfected with one of the three siRNA, see Table 2.
Before transfection, 100 uL of media was taken from each well. 
Transfection procedure was done according to Lipofectamine 
RNAiMAX Reagent protocol (Protocol Pub. No. MAN0007825 
Rev. 1.0). 3pM of siRNA per well and Lipofectamine 0.6 uL per 
well were delivered in 20uL. 80 uL of fresh cell culture media was 
added to each well.
Cells were collected 72 h after transfection using Lysis buffer 
from RNeasy Mini Kit (QIAGEN). RNA extraction was done using 
RNeasy Mini Kit (QIAGEN) according to the manufacturer’s 
protocol (no Dnase treatment step was done). Concentrations of 
RNA measured with Qubit RNA BR Assay Kit. cDNA was done 
using Bio-Rad iScript cDNA Kit according to the manufacturer’s 
protocol.
Quantitative Real-Time PCR was done for the samples using 
QuantiFast SYBR Green PCR Kit and GAPDH as a control gene. 
Primers for the targets you can see in the Table 3.
qRT PCR set up: sample was heated to 95°C, followed by 40 cycles 
of 95°C for 10 sec and 60°C for 30 sec.
Evaluation of cell growth after knock down of gene targets. 
CACYBP is up-regulated in tumor tissue, as compared to normal 
tissue (Figure 5B). Consequently, if CACYBP has regulatory 
potential, as predicted by our analysis, it should function as an 
Table 3. Primers and Targets.
Target Forward/
Reverse
Primer sequence (5’ -> 3’)
FGFR2 Forward AACAGTTTCGGCTGAGTCCAG
FGFR2 Reverse GCCCAGTGTCAGCTTATCTCTT
CACYBP Forward CTCTGTGGAAGGCAGTTCAAA
CACYBP Reverse TCAGGTAATCCCACCTTGTGTT
GAPDH Forward GGAGCGAGATCCCTCCAAAAT
GAPDH Reverse GGCTGTTGTCATACTTCTCATGG
Table 2. Suppliers.
Target Supplier Supplier ID
FGFR2 ThermoFisher s5173
CACYBP ThermoFisher s25819
Non-targeting 
siRNA
Dharmacon D-001810-01-05
oncogene promoting cell proliferation. Therefore, the knockdown 
of this gene should result in a decrease of cell growth/survival. 
Since FGFR2 was found down-regulated in cervical carcinomas 
(Figure 5B) its potential regulatory role would be as a tumor 
suppressor. Therefore, the knockdown of this gene is expected to 
increase cell growth.
Cell growth was evaluated using xCelligence system (The 
RTCA DP Instrument) using manufacturer’s protocol. ME180 
was cultured in RPMI media with 10% FBS and 1% Penicillin- 
Streptomycin added. The cells were seeded at density 4000 cells 
per well (E-Plate 16) in 200 uL of cell culture media.
24 hours after seeding, the experiment was paused for transfecton. 
Before transfection, 100 uL of media was taken from each well. 
Transfection procedure was done according to Lipofectamine 
RNAiMAX Reagent protocol (Protocol Pub. No. MAN0007825 
Rev. 1.0). 3pM of siRNA per well and Lipofectamine 0.6 uL per 
well were delivered in 20uL; 80 uL of fresh cell culture media was 
added to each well. Plate was placed back in the slot and cell growth 
was evaluated for another 72 h.
Cell index normalization. To evaluate cell growth rate cell index 
was transformed into Inhibition index in two steps: 
1.    Cell indexes for all wells were exported to the excel 
file. For each treatment (including non-targeting siRNA 
transfected wells) we extracted cell index average for all 
wells at 20 h after seeding (Cell Index Before Treatment) 
and at 96 h after seeding (Cell Index After Treatment). To 
normalize cell index to initial cell number differences for 
each of the treatments we used the following formula:
=
CellindexAfterTreatment
CellindexBeforeTreatment
After/Before Treatment 
Normalized Cell Index (A/B Index)
2.    In next step we normalized each treatment with target-
ing siRNA to treatment with non-targeting siRNA. For 
this purpose in each experiment A/B Index from treat-
ment (siRNA targeting either FGFR2 or CACYBP) was 
normalized to A/B Index from control treatment using the 
following formula:
    
=
Control A/B Index – Treatment A/B Index
Control  A/B Index
Inhibition Index
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 Final evaluation of growth was done according to the value of 
Inhibition Index:
>0 – there is a decrease in growth;
 0 – no difference between treated with targeting and treated 
with non-targeting siRNA;
<0 – there is a growth after treating with targeting siRNA.
Data availability
BcKO: Gene expression files containing array data from 28 are 
available under the GSE23934 superseries in the Gene Expression 
Omnibus (GEO) data repository. We worked with two groups of 
samples: B10.A littermates and BALB/C (Table S1).
Cervical cancer: We have used the same datasets as in previous 
study29 available at GEO: GSE741050, GSE679151, GSE780352, 
GSE975053, GSE2634229 (Table S21). 
F1000Research: Dataset 1. Differentially expressed genes from BcKO 
study, 10.5256/f1000research.9708.d14210057
F1000Research: Dataset 2. Differentially correlated pairs from BcKO 
study, 10.5256/f1000research.9708.d14209958
F1000Research: Dataset 3. Causal genes from BcKO study, 
10.5256/f1000research.9708.d14209759
F1000Research: Dataset 4. Causal genes from cervical cancer 
study, 10.5256/f1000research.9708.d14209860
F1000Research: Dataset 5. Cytoscape Edges and Nodes tables from 
network in Figure 1, 10.5256/f1000research.9708.d14210161
F1000Research: Dataset 6. Cytoscape Edges and Nodes tables from 
network in Figure 3, 10.5256/f1000research.9708.d14210262
F1000Research: Dataset 7. Raw data for Figure 5A, C, 10.5256/
f1000research.9708.d14210363
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The manuscript “Differentially correlated genes in co-expression networks control phenotype transitions”
investigates the differentially co-expressed genes in two biological processes, a homogeneous
one-causal-factor process (B cell deficiency) and a heterogeneous multi-causal system (cervical cancer).
The authors have adopted the Pearson correlation and partial correlation for the inference of networks.
Major revision:
The networks were inferred from local partial correlation method, which is able to identify a linear
relationship between two variables X and Y (genes), and this relationship may or may not be
mediate by another gene Z. It is not clear why the authors have adopted the Pearson correlation for
B cell deficiency analysis and the partial correlation for cervical cancer analysis. Moreover, it would
be interesting to highlight the gain obtained by adopting the partial correlation. For instance, what
were the relationships inferred with the partial correlation that would not be inferred using Pearson
correlation?
 
Another important issue is that even with partial correlation, only pairwise of relationships are
identified. In the study presented at http://dx.doi.org/10.1109/JSTSP.2008.923841, it presents the
Intrinsically Multivariate Predictive (IMP) Genes, which are genes that depend on a subset of
predictors. How did the authors deal with these IMP genes?
 
It is not clear how and why the microarray data was filtered. The authors could better describe how
the data was filtered and how the parameters were adopted.
 
The title “Differentially correlated genes in co-expression networks control phenotype transitions” is
too rigid leading to the understanding that all correlated genes control the phenotype transitions. I
believe that is not true. Authors could provide a more appropriate title.
Minor revisions:
Page 3: “homogenous” → homogeneous
 
Page 4: "correlation lost" → correlation loss;
References
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
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 Andrei Zinovyev
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The manuscript "Differentially correlated genes in co-expression networks control phenotype transitions"
by Lina Thomas , is devoted to describing a case study of two transcriptomic datasets with the focus et al
on characterizing pairs of differentially correlated genes, with a limited experimental validation of the
conclusions of the statistical analysis.
The manuscript is clear, technically sound and exploits an interesting approach for the analysis of
expression data. The conclusions of the statistical analysis are sufficiently justified. I like the detailed and
illustrated description of the novel methods exploited the paper. Experimental validation of several
findings is a big plus. Therefore, I think the article deserves to be indexed.
I have several remarks for the manuscript which I think should be addressed before approval:
I am not completely comfortable with the title of the manuscript, which is quite conceptual, while the
content of the paper remains descriptive and does not provide mechanistic insight on how DCG
pairs can control the phenotype. I suggest to the authors to have some reflexion on how to make it
more adequate.
 
Related to 1), in Introduction the desciption of the mechanisms by which DCG pairs can "contribute
to propagation of perturbation" remain very illusive. I suggest to the authors to formulate more
clearly at least several hypotheses or scenario by which DCG pairs might appear and play an
important role. A figure illustrating such hypotheses would clarify what the authors mean.
 
Figures 1 and 3 are not very informative. Can authors make an effort to improve this aspect (at
least, visualize some DC gene names?)
 
The authors do not discuss a possibility that appearance of DC pairs can be a result of differential
sample tissue composition from several cell types (i.e., immune cells in jejunum or in a tumor
tissue). Discussing this point would be an advantage.
 
In several places, the authors apply terms "upstream", "downstream" with respect to the network
which is undirected by its nature. I suggest to underline that the nature of correlation networks does
not allow distinguishing causality direction and considering genes "downstream" of the key drivers
is only a hypothesis which can not be assessed from the data.
 
Description of the transcriptomic datasets in Materials and Methods is too brief, especially for the
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Description of the transcriptomic datasets in Materials and Methods is too brief, especially for the
cervix dataset which seems to be quite composite. It would be appropriate to specify more clearly
the dataset's composition (not simply referring to the original publications) directly in the paper text.
 
One thing which is confusing to me is that the correlation networks are constructed differently for
two case studies (direct vs partial). I understood the reason why partial correlation was prefered for
the cervical cancer study, however, the question is: can the conclusion about that DC pairs do not
contain key drivers in the case of cervical cancer be affected by the difference in the methodology
of correlation graph computation? It would be usefull to clarify this aspect.
 
The section "Filtering and meta-analysis of microarray data" was not clear to me. I suggest to
re-write it.
Minor remarks:
Page 4: "correlation lost" -> "correlation loss"
Description of the partial correlation method refers to a paper (30) which can not be easily accessed.
Direct reference to the arXiv preprint would be more appropriate in this case
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
 20 December 2016Referee Report
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Center for Bioscience and Biotechnology, State University of Norte Fluminense Darcy Ribeiro, Campos
dos Goytacazes, RJ, 28035-200, Brazil
In the present work Thomas employed method to find differentially co-expressed genes inet al. 
co-expression networks of a B lymphocyte deficiency (largely mono-causal) and a complex cervical
cancer (multi-causal) dataset. They used different graph-theoretical approaches to find relevant genes in
this context.
Interestingly, the authors found that 72% (39/54) of the correlation gains involve at least one Ig gene,
which is in agreement with the previously shown association between intestinal gene expression and B
cells ability to produce antibodies. Is it possible that this "correlation gains" are merely a consequence of
the general enrichment of Ig genes in the DC list?
In the cervical cancer analysis, the authors used shortest-path and betweenness centrality to argue for the
regulatory relevance of DC genes. I think it would be great to supplement this finding with more
biochemical information. For example, how many of these genes are transcription factors or protein
kinases?
Overall, I think this study is technically sound and properly executed.
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Overall, I think this study is technically sound and properly executed.
== Minor corrections
In the abstract, "mus musculus" should read "Mus musculus".
In Figure 2, Ig is underlined as if marked by a spellchecker.
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